A comprehensive study has found a potential association between GLP-1 receptor agonist drugs, commonly used for diabetes and obesity treatment, and an elevated risk of alopecia.

The research analysed data from over 50,000 patients, comparing those using GLP-1s with users of alternative diabetes medications like SGLT-2 inhibitors and DPP-4 inhibitors.

Results indicated a 37% higher risk of non-scarring hair loss among GLP-1 users compared to SGLT-2 inhibitors, while the risk rose to 68% when compared to DPP-4 inhibitors.The findings suggest that factors such as calorie restriction, micronutrient deficiencies, and hormonal changes may contribute to this side effect.

Researchers from the University of Pennsylvania Health System highlighted that regulators in the US have noted reports of hair loss linked to semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro).Although hair loss is not physically harmful, it can impact self-esteem and treatment adherence.The study adds systematic evidence to previous anecdotal reports, urging clinicians to be aware of this potential adverse effect.